Hengrui Pharma announced that it has entered into a license agreement with Novo Nordisk (Novo) for HRS-1596, a phase I-ready ...
Link Cell Therapies ("Link"), an oncology cell therapy company utilizing its proprietary logic-gating technology to develop ...
NouvSight001 secures regulatory clearances from the US FDA and China’s NMPA for clinical development in retinitis pigmentosa, ...
It has been evaluated across multiple clinical studies in patients with CLL/SLL who were either previously treated with a ...
The Stockholm Region deployment marks another important milestone in Lunit's expansion across Europe, demonstrating how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results